About HiberCell
HiberCell is a company based in New York (United States) founded in 2015. It operates as a HealthTech. HiberCell has raised $128.15 million across 3 funding rounds from investors including Mount Sinai, Hercules Capital and Celgene. HiberCell has completed 1 acquisition, including Genuity Science. HiberCell offers products and services including HC-7366, HC-5404, and Odetiglucan. HiberCell operates in a competitive market with competitors including TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hibercell Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$128.15 M (USD)
in 3 rounds
-
Latest Funding Round
$30 M (USD), Debt – Conventional
May 19, 2021
-
Investors
Mount Sinai
& 10 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HiberCell
HiberCell offers a comprehensive portfolio of products and services, including HC-7366, HC-5404, and Odetiglucan. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Designed to activate GCN2 kinase for stress response.
Developed to inhibit PERK for stress mitigation pathways.
Formulated to modulate immune response in tumor microenvironment.
Unlock access to complete
Unlock access to complete
Funding Insights of HiberCell
HiberCell has successfully raised a total of $128.15M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $30 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Debt – Conventional — $30.0M
-
First Round
First Round
(07 Feb 2019)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Series B - HiberCell | Valuation | Monashee Investment Management , Hercules Capital | |
| May, 2021 | Amount | Debt – Conventional - HiberCell | Valuation |
investors |
|
| Feb, 2019 | Amount | Series A - HiberCell | Valuation | Arch Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in HiberCell
HiberCell has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Mount Sinai, Hercules Capital and Celgene. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Magnetic Ventures is focused on transforming healthcare through AI and biotech investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by HiberCell
HiberCell has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genuity Science. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI-based omics data analysis solutions are provided to researchers.
|
2013 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - HiberCell
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hibercell Comparisons
Competitors of HiberCell
HiberCell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer are developed by targeting ecDNA.
|
|
| domain | founded_year | HQ Location |
T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hibercell
Frequently Asked Questions about HiberCell
When was HiberCell founded?
HiberCell was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Where is HiberCell located?
HiberCell is headquartered in New York, United States. It is registered at New York, New York, United States.
Is HiberCell a funded company?
HiberCell is a funded company, having raised a total of $128.15M across 3 funding rounds to date. The company's 1st funding round was a Series A of $60.75M, raised on Feb 07, 2019.
What does HiberCell do?
HiberCell is engaged in pioneering cancer treatment paradigms by targeting adaptive stress mechanisms in tumors. The company is dedicated to addressing treatment resistance, relapse, and metastasis through innovative therapeutic candidates like HC-7366, HC-5404, and Odetiglucan. These solutions are designed to exploit stress-driven vulnerabilities in cancer cells, inhibit stress-mitigating pathways, and enhance immune responses in the tumor microenvironment. Operations are centered in the healthcare and biotechnology sector with a focus on improving patient outcomes through advanced clinical development.
Who are the top competitors of HiberCell?
HiberCell's top competitors include Lyell Immunopharma, GigaGen and Shattuck Labs.
What products or services does HiberCell offer?
HiberCell offers HC-7366, HC-5404, and Odetiglucan.
How many acquisitions has HiberCell made?
HiberCell has made 1 acquisition, including Genuity Science.
Who are HiberCell's investors?
HiberCell has 11 investors. Key investors include Mount Sinai, Hercules Capital, Celgene, Arch Venture Partners, and Bristol-Myers Squibb.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.